QUESTION: Can the theranostic pair 68 Ga/ 177 Lu-NYM096 offer a new approach to the treatment of metastatic clear cell renal cell carcinoma (ccRCC)?
PERTINENT FINDINGS: The radiotracer 68 Ga-NYM096 showed excellent tumor uptake in ccRCC lesions. 177 Lu-NYM096 treatment was feasible and showed early evidence of tumor response.
IMPLICATIONS FOR PATIENT CARE: This theranostic pair demonstrates promising potential in targeted radiopharmaceutical therapy, offering a new strategy for patients with end-stage ccRCC.
Reston, VA (August 26, 2026)— A newly developed radiotheranostic pair, 68 Ga/ 177 Lu-NYM096, can identify tumors and effectively deliver targeted radiotherapy to patients with metastatic clear cell renal cell carcinoma (ccRCC). Using a small molecule compound, the new approach helps to mitigate toxicity issues common with treatment, offering a safe and feasible strategy for those with end-stage disease. This research was published in the September issue of The Journal of Nuclear Medicine .
ccRCC is the most common subtype of renal cancer, accounting for approximately 70 to 80 percent of all cases. Many patients have unresectable or metastatic disease upon initial diagnosis or develop advanced-stage disease after initial localized treatment. While immunotherapy-based combination therapies have emerged as effective treatment strategies, a notable proportion of patients don’t respond to therapy or experience significant toxicities.
“My colleagues and I developed a new generation of small molecule compounds that target carbonic anhydrase IX (CAIX) enzymes which are overexpressed in ccRCC,” said Wenjia Zhu, MD, associate professor in the Department of Nuclear Medicine at Peking Union Medical College Hospital in Beijing, China. “These compounds allow for radiolabeling with both diagnostic and therapeutic radioisotopes to more precisely—and safely—deliver treatment to patients."
Researchers conducted preclinical and first-in-human experiments to explore the characteristics of the theranostic pair 68 Ga/ 177 Lu-NYM096, focusing on its safety, tolerability, dosimetry, and preliminary efficacy for metastatic ccRCC. First, in vivo biodistribution of 68 Ga-NYM096 and the therapeutic efficacy of 177 Lu-NYM096 was evaluated in ccRCC-tumor bearing mice. Next, patients with metastatic ccRCC who had disease progression after standard therapy underwent serial whole-body 68 Ga-NYM096 PET/CT to evaluate biodistribution and dosimetry. Those with positive CAIX expression received 177 Lu-NYM096 following a standard 3-plus-3 dose escalation design. Serial whole-body planar imaging was performed after the first therapy cycle. Safety, dosimetry, and preliminary efficacy were evaluated.
In the murine models, high tumor accumulation of 68 Ga/ 177 Lu-NYM096 was observed. 177 Lu-NYM096 was well tolerated and demonstrated a significant dose-dependent tumor suppression effect. In patients, 68 Ga-NYM096 demonstrated excellent tumor uptake and 177 Lu-NYM096 treatment demonstrated no evidence of nephrotoxicity, hepatotoxicity, or pancreatic toxicity. Gastric toxicity, however, was observed. Follow-up 68 Ga-NYM096 PET/CT evaluations showed evidence of tumor response to 177 Lu-NYM096 treatment.
“Our imaging agent identified tumors with very high uptake, and our early clinical experience suggests that targeted radiotherapy may offer a new treatment strategy for selected patients,” noted Li Huo, MD, director of the Department of Nuclear Medicine at Peking Union Medical College Hospital in Beijing, China. “This study provides the first human evidence of both the promise of this approach and highlights an important challenge—radiation to the stomach—that will help guide the development of safer future treatments.”
The authors of “ Preclinical and First-in-Human Study of Carbonic Anhydrase IX–Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma ” include Jingnan Wang, Xinchun Yan, Meixi Liu, Xueqian Yang, Wenjia Zhu, and Li Huo, Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Guoyang Zheng and Yushi Zhang, Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; and Xiaoyuan Cheng and Chunmei Bai, Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Visit the JNM website for the latest research, follow us on Twitter and Facebook (@JournalofNucMed), and join us on LinkedIn .
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org .
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
Journal of Nuclear Medicine
Preclinical and First-in-Human Study of Carbonic Anhydrase IX–Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma